The FINANCIAL — Amgen on October 12 announced results from a seven-year, single-arm, open-label extension of the three-year randomized, double-blind, placebo-controlled, multicenter, international ...

Teva shared that the Food and Drug Administration has accepted, and the European Medicines Agency has validated, applications for TVB-009P, a biosimilar candidate to Amgen’s Prolia (denosumab). Both ...

Compared with oral bisphosphonates, denosumab reduced fracture risk among treatment-experienced postmenopausal women with osteoporosis. Treatment with denosumab vs oral bisphosphonates is associated ...

The study of postmenopausal women in Iran found the efficacy of the biosimilar was noninferior to the reference product and the safety was comparable after 18 months. As the global population ...

Clinical data from a phase 3 trial show Ponlimsi has comparable safety and efficacy to Prolia in women with postmenopausal osteoporosis. The Food and Drug Administration (FDA) has approved Ponlimsi ™ ...

Shanghai Henlius Biotech and Organon have received permission from the Food and Drug Administration for Bildyos (denosumab-nxxp) injection 60 mg/ml and Bilprevda (denosumab-nxxp) injection 120 mg/1.7 ...

Researchers published the study covered in this summary on researchsquare.com as a preprint that has not yet been peer reviewed. Study participants had no clinical fractures during 24 months of follow ...

Adding denosumab to adjuvant aromatase inhibitor therapy improved disease-free survival for postmenopausal patients with early-stage, hormone receptor (HR)-positive breast cancer, according to results ...

Please provide your email address to receive an email when new articles are posted on . Hypocalcemia risk increased with worsening CKD stages, particularly for patients on dialysis. Emergently treated ...

BOLERO-4: Multicenter, open-label, phase II study of everolimus plus letrozole as first-line therapy in ER+, HER2- metastatic breast cancer. Background: In women with early-stage breast cancer, bone ...